Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- ambrisentan
- darolutamide
Interactions between your drugs
ambrisentan darolutamide
Applies to: ambrisentan, darolutamide
MONITOR: Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by darolutamide. Increased adverse reactions of the OATP 1B1 and 1B3 substrates may result.
MANAGEMENT: Caution is advised when darolutamide is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever darolutamide is added to or withdrawn from therapy.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2019) "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc.
Drug and food interactions
darolutamide food
Applies to: darolutamide
ADJUST DOSING INTERVAL: Food enhances the oral absorption of darolutamide. According to the prescribing information, bioavailability of darolutamide increased by 2.0 to 2.5-fold when administered with food. A similar increase in exposure was observed for the active metabolite keto-darolutamide.
MANAGEMENT: Darolutamide should be administered with food.
References (1)
- (2019) "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Cialis
Cialis (tadalafil) increase increases blood flow to a certain area of the body and is used to treat ...
Viagra
Viagra (sildenafil) is used to treat erectile dysfunction or impotence in men. Includes Viagra side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Adcirca
Adcirca is used to treat pulmonary arterial hypertension. Learn about side effects, interactions ...
Revatio
Revatio (sildenafil) is used to treat pulmonary arterial hypertension. Includes Revatio side ...
Opsumit
Opsumit (macitentan) is used to treat pulmonary arterial hypertension. Includes Opsumit side ...
Adempas
Adempas (riociguat) is used to treat pulmonary hypertension. Includes Adempas side effects ...
Winrevair
Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered ...
Uptravi
Uptravi lowers blood pressure in your lungs by dilating blood vessels that supply blood to the ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.